FDA seeks input on prostate Ca clinical trial endpoints

PSMA staging did not appear to have a significant impact on radiation therapy utilization.

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

“Among active surveillance patients, 82% are metastases free, and 60% were metastases free and had an intact, un-radiated bladder,” said Pooja Ghatalia, MD.

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

Anktiva is also currently under review for the CIS indication in the EU.